HanBio’s pipeline spans dermal papilla cell therapies, DPC-derived exosome research, stem cell programs, NK cell programs, cosmetics ingredients, and companion-animal cell applications. The lead program is HXF-101, an autologous DPC-based candidate for androgenetic alopecia.